This Article Full Text (PDF) Other Versions of this Article: AAC.00971-07v1 51/12/4382    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Critchley, I. A. Articles by Janjic, N. Search for Related Content PubMed PubMed Citation Articles by Critchley, I. A. Articles by Janjic, N.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00971-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

National and Regional Assessment of Antimicrobial Resistance among Community-acquired Respiratory Tract Pathogens identified in the U.S. 2005-2006 Faropenem Surveillance Study

Replidyne, Inc., Louisville, Colorado 80027, Clinical Microbiology Institute, Wilsonville, Oregon 97070, Replidyne, Inc., Milford, Connecticut 06460

^* To whom correspondence should be addressed. Email: icritchley{at}replidyne.com.

	Abstract

Surveillance studies conducted in the U.S. over the last decade have revealed increasing resistance among community-acquired respiratory pathogens, especially Streptococcus pneumoniae that may limit future options for empiric therapy. The objective of the study was to assess the scope and magnitude of the problem at the national and regional levels during the 2005-2006 respiratory season in the U.S. Also, since faropenem is an oral penem being developed for the treatment of community-acquired respiratory tract infections the study should provide baseline data to benchmark changes in the susceptibility of U.S. respiratory pathogens to the drug in the future. The in vitro activities of faropenem and other agents were determined against 1,543 S. pneumoniae isolates, 978 Haemophilus influenzae isolates, and 489 Moraxella catarrhalis isolates collected from 104 U.S. laboratories across 6 geographic regions during 2005-2006. Among S. pneumoniae isolates the rates of resistance to penicillin, amoxicillin/clavulanate and cefdinir were 16, 6.4 and 19.2% respectively. The least effective agents were trimethoprim/sulfamethoxazole (SXT) and azithromycin with resistance rates of 23.5 and 34% respectively. Penicillin-resistant S. pneumoniae varied by region from 8.7 to 22.5% as did multi drug resistance from 8.8 to 24.9%. Resistance to -lactams, azithromycin and SXT was higher among S. pneumoniae from children than adults. -Lactamase production among H. influenzae and M. catarrhalis was 27.4 and 91.6% respectively. Faropenem MICs at which 90% of isolates are inhibited were; 0.5 µg/mL for S. pneumoniae, 1 µg/mL for H. influenzae and 0.5 µg/mL for M. catarrhalis suggesting it shows promise as a treatment option for respiratory infections caused by contemporary resistant phenotypes.

This article has been cited by other articles:

• Critchley, I. A., Jacobs, M. R., Brown, S. D., Traczewski, M. M., Tillotson, G. S., Janjic, N. (2008). Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem. Antimicrob. Agents Chemother. 52: 2639-2643 [Abstract] [Full Text]  
• El Moussaoui, R, Roede, B M, Speelman, P, Bresser, P, Prins, J M, Bossuyt, P M M (2008). Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 63: 415-422 [Abstract] [Full Text]